Online inquiry

IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8459MR)

This product GTTS-WQ8459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8459MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9120MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ10761MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ10624MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ7025MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ11699MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ13173MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ5538MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ15536MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW